The pan-tumor AMADEUS trial aimed to prospectively evaluate the efficacy of nivolumab monotherapy in CD8-high tumors and the impact of nivolumab and ipilimumab combination treatment on tumoral CD8 T cell infiltration and response rates in CD8-low tumors. This evidence concerns the gene CD8A and neoplasm.